Minn H - Search Results

1

Prediction of prostate cancer aggressiveness using ¹⁸F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI.

Movahedi P, Merisaari H, Perez IM, Taimen P, Kemppainen J, Kuisma A, Eskola O, Teuho J, Saunavaara J, Pesola M, Kähkönen E, Ettala O, Liimatainen T, Pahikkala T, Boström P, Aronen H, Minn H, Jambor I. Movahedi P, et al. Among authors: minn h. Sci Rep. 2020 Jun 10;10(1):9407. doi: 10.1038/s41598-020-66255-8. Sci Rep. 2020. PMID: 32523075 Free PMC article. Clinical Trial.

2

Pharmacokinetics of [18F]FETNIM: a potential marker for PET.

Grönroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P, Bergman J, Haaparanta M, Forsback S, Solin O. Grönroos T, et al. Among authors: minn h. J Nucl Med. 2001 Sep;42(9):1397-404. J Nucl Med. 2001. PMID: 11535732 Free article.

3

Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET.

Lehtiö K, Oikonen V, Grönroos T, Eskola O, Kalliokoski K, Bergman J, Solin O, Grénman R, Nuutila P, Minn H. Lehtiö K, et al. Among authors: minn h. J Nucl Med. 2001 Nov;42(11):1643-52. J Nucl Med. 2001. PMID: 11696633 Free article.

4

18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies.

Tolvanen T, Lehtiö K, Kulmala J, Oikonen V, Eskola O, Bergman J, Minn H. Tolvanen T, et al. Among authors: minn h. J Nucl Med. 2002 Dec;43(12):1674-80. J Nucl Med. 2002. PMID: 12468519 Free article.

5

Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.

Lehtiö K, Oikonen V, Nyman S, Grönroos T, Roivainen A, Eskola O, Minn H. Lehtiö K, et al. Among authors: minn h. Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):101-8. doi: 10.1007/s00259-002-1016-x. Epub 2002 Oct 30. Eur J Nucl Med Mol Imaging. 2003. PMID: 12483416 Clinical Trial.

6

Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, Minn H. Sutinen E, et al. Among authors: minn h. Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):317-24. doi: 10.1007/s00259-003-1377-9. Epub 2003 Nov 20. Eur J Nucl Med Mol Imaging. 2004. PMID: 14628097 Clinical Trial.

7

Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.

Grönroos T, Bentzen L, Marjamäki P, Murata R, Horsman MR, Keiding S, Eskola O, Haaparanta M, Minn H, Solin O. Grönroos T, et al. Among authors: minn h. Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):513-20. doi: 10.1007/s00259-003-1404-x. Epub 2004 Jan 14. Eur J Nucl Med Mol Imaging. 2004. PMID: 14722675

8

Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer.

Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, Grénman R, Minn H. Lehtiö K, et al. Among authors: minn h. Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):971-82. doi: 10.1016/j.ijrobp.2003.12.014. Int J Radiat Oncol Biol Phys. 2004. PMID: 15234030

9

Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.

Havu-Aurén K, Kiiski J, Lehtiö K, Eskola O, Kulvik M, Vuorinen V, Oikonen V, Vähätalo J, Jääskeläinen J, Minn H. Havu-Aurén K, et al. Among authors: minn h. Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):87-94. doi: 10.1007/s00259-006-0154-y. Epub 2006 Jul 29. Eur J Nucl Med Mol Imaging. 2007. PMID: 16896669

10

Imaging of tumor hypoxia to predict treatment sensitivity.

Minn H, Grönroos TJ, Komar G, Eskola O, Lehtiö K, Tuomela J, Seppänen M, Solin O. Minn H, et al. Curr Pharm Des. 2008;14(28):2932-42. doi: 10.2174/138161208786404380. Curr Pharm Des. 2008. PMID: 18991711 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

211 results

Search Page